WHAT IS CLAIMED IS:

1. A peptide comprising 3-13 amino acids from residues 244-400 of SEQ ID NO:01 or from residues 1-150 of SEQ ID NO:750.

2. The peptide of claim 1, wherein the peptide is from the microtubule binding region (MTBR) of tau (residues 244-372 of SEQ ID NO:01).

3. The peptide of claim 1, wherein the peptide comprises an amino acid sequence selected from the group consisting of any one of SEQ ID NO:02 to SEQ ID NO:19, SEQ ID NO:25 to SEQ ID NO:320, SEQ ID NO:411, SEQ ID NO:454, SEQ ID NO:456, SEQ ID NO:458 to SEQ ID NO:742, SEQ ID NO:747 to SEQ ID NO:749, or SEQ ID NO:755 to SEQ ID NO:776.

~~4. The peptide of claim 3, wherein the peptide comprises an amino acid sequence selected from the group consisting of any one of SEQ ID NO:02 to SEQ ID NO:19, SEQ ID NO:28 to SEQ ID NO:102, SEQ ID NO:185 to SEQ ID NO:320, SEQ ID NO:458 to SEQ ID NO:742, or SEQ ID NO:747 to SEQ ID NO:749.~~

~~5~~4. The peptide of any one of claims ~~1-4~~1-3, wherein the peptide further comprises a C-terminal cysteine (-C) or an N-terminal cysteine (C-).

~~6~~5. The peptide of any one of claims ~~1-4~~1-3, wherein the peptide further comprises a C-terminal -GGC or -GGGC and/or~~.~~

~~7. The peptide of any one of claims 1-4, wherein~~ the peptide further comprises a N-terminal CGG or CGGG-.

~~8~~6. The peptide of any one of claims 1-~~7~~5, wherein the peptide comprises 7-13 amino acids from residues 244-400 of SEQ ID NO:01 or from residues 1-150 of SEQ ID NO:750.

~~9. The peptide of any one of claims 1-7, wherein the peptide comprises 8 amino acids from residues 244-400 of SEQ ID NO:01.~~

~~10. The peptide of any one of claims 1-7, wherein the peptide comprises 8 amino acids from residues 1-150 of SEQ ID NO:750.~~

~~11~~7. The peptide of any one of claims 1-~~7~~5, wherein the peptide comprises an amino acid sequence selected from the group consisting of any one of SEQ ID NO:777 to SEQ ID NO:908.

~~12~~8. A peptide comprising an amino acid sequence selected from the group consisting of any one of SEQ ID NO:20 to SEQ ID NO:24, SEQ ID NO:312 to SEQ ID NO:457, each optionally further comprising a C-terminal cysteine.

~~13~~9. The peptide of any one of ~~claims 1-7~~claim 1, wherein the peptide comprises an amino acid sequence selected from the group consisting of

QIVYKPV (SEQ ID NO:02),
QIVYKP (SEQ ID NO:03),
NIKHVP (SEQ ID NO:04),
NIKHVPG (SEQ ID NO:05),
HVPGGG (SEQ ID NO:06),
HVPGG (SEQ ID NO:07),
HKPGGG (SEQ ID NO:08),
HKPGG (SEQ ID NO:09),
KHVPGGG (SEQ ID NO:10),
KHVPGG (SEQ ID NO:11),
HQPGGG (SEQ ID NO:12),
HQPGG (SEQ ID NO:13),
VQIINK (SEQ ID NO:14),
VQIINKK (SEQ ID NO:15),
VQIINKKL (SEQ ID NO:16),
QIINK (SEQ ID NO:17),
QIINKK (SEQ ID NO:18),
QIINKKL (SEQ ID NO:19),
EIVYKSP (SEQ ID NO:25),
IVYKSPV (SEQ ID NO:26),
IVYK (SEQ ID NO:27),
QIVYKS (SEQ ID NO:325),
EIVYKS (SEQ ID NO:131),
EIVYKP (SEQ ID NO:411),
GYTMHQD (SEQ ID NO:454),
QGGYTMHQD (SEQ ID NO:456),
VKSKIGSTE (SEQ ID NO:589),
KSKIGSTE (SEQ ID NO:590),
SKIGSTEN (SEQ ID NO:598),
KIGSTENL (SEQ ID NO:605),
IGSTENLK (SEQ ID NO:611),
GSTENLKH (SEQ ID NO:616),
STENLKHQ (SEQ ID NO:620),
TENLKHQP (SEQ ID NO:476),
ENLKHQPG (SEQ ID NO:470),
VKSKIGST (SEQ ID NO:582),
PDLKNVKS (SEQ ID NO:755),
DLKNVKSK (SEQ ID NO:756),
LKNVKSKI (SEQ ID NO:757),
KNVKSKIG (SEQ ID NO:758),
NVKSKIGS (SEQ ID NO:759),
NLKHQPGG (SEQ ID NO:465),
LKHQPGGG (SEQ ID NO:460),
LDLSNVQS (SEQ ID NO:760),
DLSNVQSK (SEQ ID NO:761),

LSNVQSKC (SEQ ID NO:762),
SNVQSKCG (SEQ ID NO:763),
NVQSKCGS (SEQ ID NO:764),
VQSKCGSK (SEQ ID NO:626),
QSKCGSKD (SEQ ID NO:634),
SKCGSKDN (SEQ ID NO:642),
KCGSKDNI (SEQ ID NO:649),
CGSKDNIK (SEQ ID NO:258),
GSKDNIKH (SEQ ID NO:653),
SKDNIKHV (SEQ ID NO:271),
KDNIKHVP (SEQ ID NO:278),
DNIKHVPG (SEQ ID NO:285),
NIKHVPGG (SEQ ID NO:292),
IKHVPGGG (SEQ ID NO:297),
VDLSKVTS (SEQ ID NO:765),
DLSKVTSK (SEQ ID NO:766),
LSKVTSKC (SEQ ID NO:767),
SKVTSKCG (SEQ ID NO:768),
KVTSKCGS (SEQ ID NO:769),
VTSKCGSL (SEQ ID NO:770),
TSKCGSLG (SEQ ID NO:666),
SKCGSLGN (SEQ ID NO:674),
KCGSLGNI (SEQ ID NO:681),
CGSLGNIH (SEQ ID NO:687),
GSLGNIHH (SEQ ID NO:692),
SLGNIHHK (SEQ ID NO:696),
LGNIHHKP (SEQ ID NO:524),
GNIHHKPG (SEQ ID NO:518),
NIHHKPGG (SEQ ID NO:513),
IHHKPGGG (SEQ ID NO:508),
LDFKDRVQ (SEQ ID NO:771),
DFKDRVQS (SEQ ID NO:772),
FKDRVQSK (SEQ ID NO:773),
KDRVQSKI (SEQ ID NO:774),
DRVQSKIG (SEQ ID NO:775),
RVQSKIGS (SEQ ID NO:776),
VQSKIGSL (SEQ ID NO:702),
QSKIGSLD (SEQ ID NO:709),
SKIGSLDN (SEQ ID NO:717),
KIGSLDNI (SEQ ID NO:724),
IGSLDNIT (SEQ ID NO:729),
GSLDNITH (SEQ ID NO:734),
SLDNITHV (SEQ ID NO:738),
LDNITHVP (SEQ ID NO:561),
DNITHVPG (SEQ ID NO:555),
NITHVPGG (SEQ ID NO:551), and

ITHVPGGG (SEQ ID NO:547).

~~14~~10. The peptide of claim ~~12~~8, wherein the peptide comprises and amino acid sequence selected from the group consisting of

QIVYKSV (SEQ ID NO:20),
EIVYKSV (SEQ ID NO:21),
EIVYKPV (SEQ ID NO:22),
CNIKHVP (SEQ ID NO:23),
CNIKHVPG (SEQ ID NO:24),
EAAGHVTQC (SEQ ID NO:449),
EAAGHVTQAR (SEQ ID NO:450),
AAGHVTQAC (SEQ ID NO:451),
AGHVTQARC (SEQ ID NO:452),
AGHVTQAR (SEQ ID NO:453),
QGGYTMHC (SEQ ID NO:455), and
GGYTMHQC (SEQ ID NO:457).

~~15~~11. The peptide of either one of claims ~~13 or 14~~9 or 10, wherein the peptide further comprises a C-terminal cysteine (-C), -GGC or -GGGC or an N-terminal cysteine (C-), CGG- or CGGG-.

~~16. The peptide of claim 13, wherein the peptide comprises an amino acid sequence selected from the group consisting of~~

~~VKSKIGSTE (SEQ ID NO:589),~~
~~KSKIGSTE (SEQ ID NO:590),~~
~~SKIGSTEN (SEQ ID NO:598),~~
~~KIGSTENL (SEQ ID NO:605),~~
~~IGSTENLK (SEQ ID NO:611),~~
~~GSTENLKH (SEQ ID NO:616),~~
~~STENLKHQ (SEQ ID NO:620),~~
~~TENLKHQP (SEQ ID NO:476), and~~
~~ENLKHQPG (SEQ ID NO:470).~~

~~17~~12. The peptide of claim ~~11~~7, wherein the peptide comprises an amino acid sequence selected from the group consisting of

VKSKIGSTEGGC (SEQ ID NO:777),
KSKIGSTEGGC (SEQ ID NO:778),
SKIGSTENGGC (SEQ ID NO:779),
KIGSTENLGGC (SEQ ID NO:780),
IGSTENLKGGC (SEQ ID NO:781),
GSTENLKHGGC (SEQ ID NO:782),
STENLKHQGGC (SEQ ID NO:783),
TENLKHQPGGC (SEQ ID NO:784),
ENLKHQPGGGC (SEQ ID NO:785),

VKSKIGSTGGC (SEQ ID NO:786),
PDLKNVKSGGC (SEQ ID NO:787),
DLKNVKSKGGC (SEQ ID NO:788),
LKNVKSKIGGC (SEQ ID NO:789),
KNVKSKIGGGC (SEQ ID NO:790),
NVKSKIGSGGC (SEQ ID NO:791),
NLKHQPGGGGC (SEQ ID NO:792), ~~and~~
LKHQPGGGGGC (SEQ ID NO:793~~).~~),

~~18. The peptide of claim 11, wherein the peptide comprises an amino acid sequence selected from the group consisting of~~

LDLSNVQSGGC (SEQ ID NO:794),
DLSNVQSKGGC (SEQ ID NO:795),
LSNVQSKCGGC (SEQ ID NO:796),
SNVQSKCGGGC (SEQ ID NO:797),
NVQSKCGSGGC (SEQ ID NO:798),
VQSKCGSKGGC (SEQ ID NO:799),
QSKCGSKDGGC (SEQ ID NO:800),
SKCGSKDNGGC (SEQ ID NO:801),
KCGSKDNIGGC (SEQ ID NO:802),
CGSKDNIKGGC (SEQ ID NO:803),
GSKDNIKHGGC (SEQ ID NO:804),
SKDNIKHVGGC (SEQ ID NO:805),
KDNIKHVPGGC (SEQ ID NO:806),
DNIKHVPGGGC (SEQ ID NO:807),
NIKHVPGGGGC (SEQ ID NO:808), ~~and~~
IKHVPGGGGGC (SEQ ID NO:809),

~~19. The peptide of claim 11, wherein the peptide comprises an amino acid sequence selected from the group consisting of~~

VDLSKVTSGGC (SEQ ID NO:810),
DLSKVTSKGGC (SEQ ID NO:811),
LSKVTSKCGGC (SEQ ID NO:812),
SKVTSKCGGGC (SEQ ID NO:813),
KVTSKCGSGGC (SEQ ID NO:814),
VTSKCGSLGGC (SEQ ID NO:815),
TSKCGSLGGGC (SEQ ID NO:816),
SKCGSLGNGGC (SEQ ID NO:817),
KCGSLGNIGGC (SEQ ID NO:818),
CGSLGNIHGGC (SEQ ID NO:819),
GSLGNIHHGGC (SEQ ID NO:820),
SLGNIHHKGGC (SEQ ID NO:821),
LGNIHHKPGGC (SEQ ID NO:822),
GNIHHKPGGGC (SEQ ID NO:823),
NIHHKPGGGGC (SEQ ID NO:824), ~~and~~
IHHKPGGGGGC (SEQ ID NO:825),

~~20. The peptide of claim 11, wherein the peptide comprises an amino acid sequence selected from the group consisting of~~

LDFKDRVQGGC	(SEQ ID NO:826),
DFKDRVQSGGC	(SEQ ID NO:827),
FKDRVQSKGGC	(SEQ ID NO:828),
KDRVQSKIGGC	(SEQ ID NO:829),
DRVQSKIGGGC	(SEQ ID NO:830),
RVQSKIGSGGC	(SEQ ID NO:831),
VQSKIGSLGGC	(SEQ ID NO:832),
QSKIGSLDGGC	(SEQ ID NO:833),
SKIGSLDNGGC	(SEQ ID NO:834),
KIGSLDNIGGC	(SEQ ID NO:835),
IGSLDNITGGC	(SEQ ID NO:836),
GSLDNITHGGC	(SEQ ID NO:837),
SLDNITHVGGC	(SEQ ID NO:838),
LDNITHVPGGC	(SEQ ID NO:839),
DNITHVPGGGC	(SEQ ID NO:840),
NITHVPGGGGC	(SEQ ID NO:841), ~~and~~
ITHVPGGGGGC	(SEQ ID NO:842).~~,~~

~~21. The peptide of claim 17, wherein the peptide comprises an amino acid sequence selected from the group consisting of~~

~~VKSKIGSTEGGC (SEQ ID NO:777),~~
~~KSKIGSTEGGC (SEQ ID NO:778),~~
~~SKIGSTENGGC (SEQ ID NO:779),~~
~~KIGSTENLGGC (SEQ ID NO:780),~~
~~IGSTENLKGGC (SEQ ID NO:781),~~
~~GSTENLKHGGC (SEQ ID NO:782),~~
~~STENLKHQGGC (SEQ ID NO:783),~~
~~TENLKHQPGGC (SEQ ID NO:784), and~~
~~ENLKHQPGGGC (SEQ ID NO:785).~~

~~22. The peptide of claim 18, wherein the peptide comprises an amino acid sequence selected from the group consisting of~~

~~VQSKCGSKGGC (SEQ ID NO:799),~~
~~QSKCGSKDGGC (SEQ ID NO:800),~~
~~SKCGSKDNGGC (SEQ ID NO:801),~~
~~KCGSKDNIGGC (SEQ ID NO:802),~~
~~CGSKDNIKGGC (SEQ ID NO:803),~~
~~GSKDNIKHGGC (SEQ ID NO:804),~~
~~SKDNIKHVGGC (SEQ ID NO:805),~~
~~KDNIKHVPGGC (SEQ ID NO:806), and~~
~~DNIKHVPGGGC (SEQ ID NO:807).~~

~~23. The peptide of claim 19, wherein the peptide comprises an amino acid sequence selected from the group consisting of~~

~~VTSKCGSLGGC (SEQ ID NO:815),~~
~~TSKCGSLGGGC (SEQ ID NO:816),~~
~~SKCGSLGNGGC (SEQ ID NO:817),~~
~~KCGSLGNIGGC (SEQ ID NO:818),~~
~~CGSLGNIHGGC (SEQ ID NO:819),~~
~~GSLGNIHHGGC (SEQ ID NO:820),~~
~~SLGNIHHKGGC (SEQ ID NO:821),~~
~~LGNIHHKPGGC (SEQ ID NO:822), and~~
~~GNIHHKPGGGC (SEQ ID NO:823).~~

~~24. The peptide of claim 20, wherein the peptide comprises an amino acid sequence selected from the group consisting of~~

~~RVQSKIGSGGC (SEQ ID NO:831),~~
~~VQSKIGSLGGC (SEQ ID NO:832),~~
~~QSKIGSLDGGC (SEQ ID NO:833),~~
~~SKIGSLDNGGC (SEQ ID NO:834),~~
~~KIGSLDNIGGC (SEQ ID NO:835),~~
~~IGSLDNITGGC (SEQ ID NO:836),~~
~~GSLDNITHGGC (SEQ ID NO:837),~~
~~SLDNITHVGGC (SEQ ID NO:838),~~
~~LDNITHVPGGC (SEQ ID NO:839), and~~
~~DNITHVPGGGC (SEQ ID NO:840).~~

~~25. The peptide of claim 21, comprising an amino acid sequence of KSKIGSTEGGC (SEQ ID NO:778).~~

~~26. The peptide of claim 21, comprising an amino acid sequence of SKIGSTENGGC (SEQ ID NO:779).~~

~~27. The peptide of claim 21, comprising an amino acid sequence of TENLKHQPGGC (SEQ ID NO:784).~~

~~28. The peptide of claim 21, comprising an amino acid sequence of ENLKHQPGGGC (SEQ ID NO:785).~~

~~29. The peptide of claim 11, wherein the peptide comprises an amino acid sequence selected from the group consisting of~~

VKSKIGSTEGGGC (SEQ ID NO:851),
PDLKNVKSGGGC (SEQ ID NO:852),
DLKNVKSKGGGC (SEQ ID NO:853),
LKNVKSKIGGGC (SEQ ID NO:854),
KNVKSKIGGGGC (SEQ ID NO:855),
NVKSKIGSGGGC (SEQ ID NO:856),

VKSKIGSTEGGGC (SEQ ID NO:843),
KSKIGSTEGGGC (SEQ ID NO:844),
SKIGSTENGGGC (SEQ ID NO:845),
KIGSTENLGGGC (SEQ ID NO:846),
IGSTENLKGGGC (SEQ ID NO:847),
GSTENLKHGGGC (SEQ ID NO:848),
STENLKHQGGGC (SEQ ID NO:849),
TENLKHQPGGGC (SEQ ID NO:850),
ENLKHQPGGGGC (SEQ ID NO:857),
NLKHQPGGGGGC (SEQ ID NO:858), ~~and~~
LKHQPGGGGGGC (SEQ ID NO:859),~~.~~

~~30. The peptide of claim 11, wherein the peptide comprises an amino acid sequence selected from the group consisting of~~

LDLSNVQSGGGC (SEQ ID NO:860),
DLSNVQSKGGGC (SEQ ID NO:861),
LSNVQSKCGGGC (SEQ ID NO:862),
SNVQSKCGGGGC (SEQ ID NO:863),
NVQSKCGSGGGC (SEQ ID NO:864),
VQSKCGSKGGGC (SEQ ID NO:865),
QSKCGSKDGGGC (SEQ ID NO:866),
SKCGSKDNGGGC (SEQ ID NO:867),
KCGSKDNIGGGC (SEQ ID NO:868),
CGSKDNIKGGGC (SEQ ID NO:869),
GSKDNIKHGGGC (SEQ ID NO:870),
SKDNIKHVGGGC (SEQ ID NO:871),
KDNIKHVPGGGC (SEQ ID NO:872),
DNIKHVPGGGGC (SEQ ID NO:873),
NIKHVPGGGGGC (SEQ ID NO:874), ~~and~~
IKHVPGGGGGGC (SEQ ID NO:875),~~.~~

~~31. The peptide of claim 11, wherein the peptide comprises an amino acid sequence selected from the group consisting of~~

VDLSKVTSGGGC (SEQ ID NO:876),
DLSKVTSKGGGC (SEQ ID NO:877),
LSKVTSKCGGGC (SEQ ID NO:878),
SKVTSKCGGGGC (SEQ ID NO:879),
KVTSKCGSGGGC (SEQ ID NO:880),
VTSKCGSLGGGC (SEQ ID NO:881),
TSKCGSLGGGGC (SEQ ID NO:882),
SKCGSLGNGGGC (SEQ ID NO:883),
KCGSLGNIGGGC (SEQ ID NO:884),
CGSLGNIHGGGC (SEQ ID NO:885),
GSLGNIHHGGGC (SEQ ID NO:886),
SLGNIHHKGGGC (SEQ ID NO:887),
LGNIHHKPGGGC (SEQ ID NO:888),

GNIHHKPGGGGC (SEQ ID NO:889),
NIHHKPGGGGC (SEQ ID NO:890), ~~and~~
IHHKPGGGGGC (SEQ ID NO:891)~~.~~,

~~32. The peptide of claim 11, wherein the peptide comprises an amino acid sequence selected from the group consisting of~~

LDFKDRVQGGGC (SEQ ID NO:892),
DFKDRVQSGGGC (SEQ ID NO:893),
FKDRVQSKGGGC (SEQ ID NO:894),
KDRVQSKIGGGC (SEQ ID NO:895),
DRVQSKIGGGGC (SEQ ID NO:896),
RVQSKIGSGGGC (SEQ ID NO:897),
VQSKIGSLGGGC (SEQ ID NO:898),
QSKIGSLDGGGC (SEQ ID NO:899),
SKIGSLDNGGGC (SEQ ID NO:900),
KIGSLDNIGGGC (SEQ ID NO:901),
IGSLDNITGGGC (SEQ ID NO:902),
GSLDNITHGGGC (SEQ ID NO:903),
SLDNITHVGGGC (SEQ ID NO:904),
LDNITHVPGGGC (SEQ ID NO:905),
DNITHVPGGGGC (SEQ ID NO:906),
NITHVPGGGGGC (SEQ ID NO:907), and
ITHVPGGGGGGC (SEQ ID NO:908).

~~33. The peptide of claim 11, wherein the peptide comprises an amino acid sequence selected from the group consisting of~~

~~CGGGSKIGSTDNIKH (SEQ ID NO:966),~~
~~CGGGSKIGSKDNIKH (SEQ ID NO:967),~~
~~CGGGSKIGSLDNIKH (SEQ ID NO:968),~~
~~CGGSKIGSTDNIKH (SEQ ID NO:963),~~
~~CGGSKIGSKDNIKH (SEQ ID NO:964),~~
~~CGGSKIGSLDNIKH (SEQ ID NO:965).~~

~~34. The peptide of claim 29, wherein the peptide comprises an amino acid sequence selected from the group consisting of~~

~~VKSKIGSTEGGGC (SEQ ID NO:843),~~
~~KSKIGSTEGGGC (SEQ ID NO:844),~~
~~SKIGSTENGGGC (SEQ ID NO:845),~~
~~KIGSTENLGGGC (SEQ ID NO:846),~~
~~IGSTENLKGGGC (SEQ ID NO:847),~~
~~GSTENLKHGGGC (SEQ ID NO:848),~~
~~STENLKHQGGGC (SEQ ID NO:849),~~
~~TENLKHQPGGGC (SEQ ID NO:850), and~~
~~ENLKHQPGGGGC (SEQ ID NO:857).~~

35. The peptide of claim 30, wherein the peptide comprises an amino acid sequence selected from the group consisting of

VQSKCGSKGGGC (SEQ ID NO:865),
QSKCGSKDGGGC (SEQ ID NO:866),
SKCGSKDNGGGC (SEQ ID NO:867),
KCGSKDNIGGGC (SEQ ID NO:868),
CGSKDNIKGGGC (SEQ ID NO:869),
GSKDNIKHGGGC (SEQ ID NO:870),
SKDNIKHVGGGC (SEQ ID NO:871),
KDNIKHVPGGGC (SEQ ID NO:872), and
DNIKHVPGGGGC (SEQ ID NO:873).

36. The peptide of claim 31, wherein the peptide comprises an amino acid sequence selected from the group consisting of

VTSKCGSLGGGC (SEQ ID NO:881),
TSKCGSLGGGGC (SEQ ID NO:882),
SKCGSLGNGGGC (SEQ ID NO:883),
KCGSLGNIGGGC (SEQ ID NO:884),
CGSLGNIHGGGC (SEQ ID NO:885),
GSLGNIHHGGGC (SEQ ID NO:886),
SLGNIHHKGGGC (SEQ ID NO:887),
LGNIHHKPGGGC (SEQ ID NO:888), and
GNIHHKPGGGGC (SEQ ID NO:889).

37. The peptide of claim 32, wherein the peptide comprises an amino acid sequence selected from the group consisting of

RVQSKIGSGGGC (SEQ ID NO:897),
VQSKIGSLGGGC (SEQ ID NO:898),
QSKIGSLDGGGC (SEQ ID NO:899),
SKIGSLDNGGGC (SEQ ID NO:890),
KIGSLDNIGGGC (SEQ ID NO:891),
IGSLDNITGGGC (SEQ ID NO:892),
GSLDNITHGGGC (SEQ ID NO:893),
SLDNITHVGGGC (SEQ ID NO:894),
LDNITHVPGGGC (SEQ ID NO:895), and
DNITHVPGGGGC (SEQ ID NO:896).

38. The peptide of claim 33, comprising an amino acid sequence of CGGGSKIGSKDNIKH (SEQ ID NO:967).

39. The peptide of claim 33, comprising an amino acid sequence of CGGSKIGSKDNIKH (SEQ ID NO:964).

40. The peptide of claim 34, comprising an amino acid sequence of VKSKIGSTEGGGC (SEQ ID NO:843).

~~41. The peptide of claim 34, comprising an amino acid sequence of KSKIGSTEGGGC (SEQ ID NO:844).~~

~~42. The peptide of claim 34, comprising an amino acid sequence of SKIGSTENGGGC (SEQ ID NO:845).~~

~~43. The peptide of claim 34, comprising an amino acid sequence of KIGSTENLGGGC (SEQ ID NO:846).~~

~~44. The peptide of claim 34, comprising an amino acid sequence of IGSTENLKGGGC (SEQ ID NO:847).~~

~~45. The peptide of claim 34, comprising an amino acid sequence of GSTENLKHGGGC (SEQ ID NO:848).~~

~~46. The peptide of claim 34, comprising an amino acid sequence of STENLKHQGGGC (SEQ ID NO:849).~~

~~47. The peptide of claim 34, comprising an amino acid sequence of TENLKHQPGGGC (SEQ ID NO:850).~~

~~48. The peptide of claim 34, comprising an amino acid sequence of ENLKHQPGGGGC (SEQ ID NO:857).~~

~~49. The peptide of claim 13, comprising an amino acid sequence of QIINK (SEQ ID NO:17).~~

~~50. The peptide of claim 13, comprising an amino acid sequence of QIVYKPV (SEQ ID NO:02).~~

~~51. The peptide of claim 13, comprising an amino acid sequence of NIKHVP (SEQ ID NO:04).~~

~~52. The peptide of claim 13, comprising an amino acid sequence of NIKHVPG (SEQ ID NO:05).~~

~~53. The peptide of claim 14, comprising an amino acid sequence of EIVYKSV (SEQ ID NO:21).~~

~~54. The peptide of claim 16, comprising an amino acid sequence of VKSKIGSTE (SEQ ID NO:589).~~

~~55. The peptide of claim 16, comprising an amino acid sequence of KSKIGSTE (SEQ ID NO:590).~~

~~56. The peptide of claim 16, comprising an amino acid sequence of SKIGSTEN (SEQ ID NO:598).~~

~~57. The peptide of claim 16, comprising an amino acid sequence of KIGSTENL (SEQ ID NO:605).~~

~~58. The peptide of claim 16, comprising an amino acid sequence of IGSTENLK (SEQ ID NO:611).~~

~~59. The peptide of claim 16, comprising an amino acid sequence of GSTENLKH (SEQ ID NO:616).~~

~~60. The peptide of claim 16, comprising an amino acid sequence of STENLKHQ (SEQ ID NO:620).~~

~~61. The peptide of claim 16, comprising an amino acid sequence of TENLKHQP (SEQ ID NO:476).~~

~~61. The peptide of claim 16, comprising an amino acid sequence of ENLKHQPG (SEQ ID NO:470).~~

~~62~~13. A peptide comprising 5-13 amino acids from residues 244-400 of SEQ ID NO:01 or from residues 1-150 of SEQ ID NO:750, comprising at least one amino acid substitution.

~~63~~14. The peptide of claim ~~62~~15, comprising an amino acid sequence of SKIGSTENLKH (SEQ ID NO:909)

~~64~~15. The peptide of claim ~~63~~15, wherein one of the at least one amino acid substitutions comprises an isoleucine substitution for a lysine at position 10.

~~65~~16. The peptide of either one of claims ~~63 or 64~~14 or 15, wherein one of the at least one amino acid substitutions comprises a lysine or leucine substitution for a tyrosine at position 6.

~~66~~17. The peptide of any one of claims ~~63-65~~14-16, wherein one of the at least one amino acid substitutions comprises an aspartic acid or glycine substitution for a glutamic acid at position 7.

~~67~~18. The peptide of claim ~~62~~14, wherein the peptide comprises an amino acid sequence selected from the group consisting of

SKIGSTENLKH	(SEQ ID NO:909),
SKIGSTENIKH	(SEQ ID NO:910),
SKIGSKDNLKH	(SEQ ID NO:911),
SKIGSKENIKH	(SEQ ID NO:912),
SKIGSLENLKH	(SEQ ID NO:913),
SKIGSLENIKH	(SEQ ID NO:914),
SKIGSTDNLKH	(SEQ ID NO:915),
SKIGSTDNIKH	(SEQ ID NO:916),
SKIGSKDNLKH	(SEQ ID NO:917),
SKIGSKDNIKH	(SEQ ID NO:918),

SKIGSLDNLKH (SEQ ID NO:919),
SKIGSLDNIKH (SEQ ID NO:920),
SKIGSTGNLKH (SEQ ID NO:921),
SKIGSTGNIKH (SEQ ID NO:922),
SKIGSKGNLKH (SEQ ID NO:923),
SKIGSKGNIKH (SEQ ID NO:924),
SKIGSLGNLKH (SEQ ID NO:925), and
SKIGSLGNIKH (SEQ ID NO:926~~),~~).

~~68. The peptide of claim 67, wherein the peptide comprises an amino acid sequence selected from the group consisting of SKIGSTDNIKH (SEQ ID NO:916), SKIGSKDNIKH (SEQ ID NO:918), or SKIGSLDNIKH (SEQ ID NO:920).~~

~~69~~19. The peptide of any one of claims ~~62-68~~13-18, wherein the peptide further comprises a C-terminal cysteine (-C), -GGC or -GGGC or an N-terminal cysteine (C-), CGG- or CGGG-.

~~70~~20. The peptide of claim 19, wherein the peptide comprises an amino acid sequence selected from the group consisting of

CGGGSKIGSTDNIKH (SEQ ID NO:966),
CGGGSKIGSKDNIKH (SEQ ID NO:967),
CGGGSKIGSLDNIKH (SEQ ID NO:968),
CGGSKIGSTDNIKH (SEQ ID NO:963),
CGGSKIGSKDNIKH (SEQ ID NO:964), and
CGGSKIGSLDNIKH (SEQ ID NO:965).

21. The peptide of claim ~~69~~19, wherein the peptide comprises an amino acid sequence selected from the group consisting of

SKIGSTENLKHGGC (SEQ ID NO:927),
SKIGSTENIKHGGC (SEQ ID NO:928),
SKIGSKDNLKHGGC (SEQ ID NO:929),
SKIGSKENIKHGGC (SEQ ID NO:930),
SKIGSLENLKHGGC (SEQ ID NO:931),
SKIGSLENIKHGGC (SEQ ID NO:932),
SKIGSTDNLKHGGC (SEQ ID NO:933),
SKIGSTDNIKHGGC (SEQ ID NO:934),
SKIGSKDNLKHGGC (SEQ ID NO:935),
SKIGSKDNIKHGGC (SEQ ID NO:936),
SKIGSLDNLKHGGC (SEQ ID NO:937),
SKIGSLDNIKHGGC (SEQ ID NO:938),
SKIGSTGNLKHGGC (SEQ ID NO:939),
SKIGSTGNIKHGGC (SEQ ID NO:940),
SKIGSKGNLKHGGC (SEQ ID NO:941),
SKIGSKGNIKHGGC (SEQ ID NO:942),
SKIGSLGNLKHGGC (SEQ ID NO:943),

SKIGSLGNIKHGGC (SEQ ID NO:944),
SKIGSTENLKHGGGC (SEQ ID NO:945),
SKIGSTENIKHGGGC (SEQ ID NO:946),
SKIGSKDNLKHGGGC (SEQ ID NO:947),
SKIGSKENIKHGGGC (SEQ ID NO:948),
SKIGSLENLKHGGGC (SEQ ID NO:949),
SKIGSLENIKHGGGC (SEQ ID NO:950),
SKIGSTDNLKHGGGC (SEQ ID NO:951),
SKIGSTDNIKHGGGC (SEQ ID NO:952),
SKIGSKDNLKHGGGC (SEQ ID NO:953),
SKIGSKDNIKHGGGC (SEQ ID NO:954),
SKIGSLDNLKHGGGC (SEQ ID NO:955),
SKIGSLDNIKHGGGC (SEQ ID NO:956),
SKIGSTGNLKHGGGC (SEQ ID NO:957),
SKIGSTGNIKHGGGC (SEQ ID NO:958),
SKIGSKGNLKHGGGC (SEQ ID NO:959),
SKIGSKGNIKHGGGC (SEQ ID NO:960),
SKIGSLGNLKHGGGC (SEQ ID NO:961),
SKIGSLGNIKHGGGC (SEQ ID NO:962),
CGGSKIGSTDNIKH (SEQ ID NO:963),
CGGSKIGSKDNIKH (SEQ ID NO:964),
CGGSKIGSLDNIKH (SEQ ID NO:965),
CGGGSKIGSTDNIKH (SEQ ID NO:966),
CGGGSKIGSKDNIKH (SEQ ID NO:967), and
CGGGSKIGSLDNIKH (SEQ ID NO:968).

~~71~~22. The peptide of any one of claims ~~1-70~~1-21, further comprising a linker to a carrier at a C-terminal portion of the peptide or at a N-terminal portion of the peptide.

~~72~~23. The peptide of claim ~~71~~22, wherein the linker comprises an amino acid sequence.

~~73~~24. The peptide of claim ~~72~~23, wherein the linker amino acid sequence comprises between about 1-10 amino acids, about 1-9 amino acids, about 1-8 amino acids, about 1-7 amino acids, about 1-6 amino acids, about 1-5 amino acids, about 1-4 amino acids, about 1-3 amino acids, about 2 amino acids or one (1) amino acid.

~~74~~25. The peptide of claim ~~72~~23, wherein the linker comprises an amino acid sequence selected from the group consisting of AA, AAA, KK, KKK, SS, SSS AGAG, GG, GGG, GAGA, KGKG, (GGS)n, (GGGS)n, and (GGGGS)n, where n=1-3.

~~75~~26. The peptide of any one of claims 1 to ~~74~~25, wherein the peptide or linker to the carrier, if present, further comprises a C-terminal cysteine (C).

~~76~~27. The peptide of any one of claims 1 to ~~75~~26, wherein the peptide further comprises a blocked amine at the N-terminus.

~~77~~28. An immunotherapy composition, comprising one or more of the peptides of any of claims 1 to ~~76~~27.

~~78~~29. The immunotherapy composition of claim ~~77~~28, wherein the one or more peptides further comprises a linker to a carrier at a C-terminal portion of the peptide.

~~79~~30. The immunotherapy composition of claim ~~78~~29, wherein the linker to the carrier comprises an amino acid sequence selected from the group consisting of AA, AAA, KK, KKK, SS, SSS AGAG, GG, GGG, GAGA, KGKG, (GGS)n, (GGGS)n, and (GGGGS)n, where n=1-3.

~~80~~31. The immunotherapy composition of either one of claims ~~78 or 79~~29 or 30, wherein the carrier comprises serum albumins, immunoglobulin molecules, thyroglobulin, ovalbumin, tetanus toxoid (TT), diphtheria toxoid (DT), a genetically modified cross-reacting material (CRM) of diphtheria toxin, CRM197, meningococcal outer membrane protein complex (OMPC) and *H. influenzae* protein D (HiD), rEPA (*Pseudomonas aeruginosa* exotoxin A), KLH (keyhole limpet hemocyanin), and flagellin.

~~81. The immunotherapy composition of claim 80, wherein the carrier is CRM197.~~

~~82. The immunotherapy composition of claim 81, wherein the carrier is diphtheria toxoid.~~

~~83~~32. The immunotherapy composition of any one of claims ~~77 to 82~~28-31, further comprising at least one pharmaceutically acceptable diluent.

~~84~~33. The immunotherapy composition of any one of claims ~~77 to 83~~28-32, further comprising a multiple antigen presenting system (MAP).

~~85.~~34 The immunotherapy composition of claim ~~84~~33, wherein the MAP comprises one or more of a Lys-based dendritic scaffold, helper T-cell epitopes, immune stimulating lipophilic moieties, cell penetrating peptides, radical induced polymerization, self-assembling nanoparticles as antigen-presenting platforms and gold nanoparticles.

~~86~~35. A pharmaceutical composition comprising (a) one or more of the peptides of any of claims 1 to ~~76~~ 27 or (b) the immunotherapy composition of any of claims ~~77 to 85~~28-34 and at least one adjuvant.

~~87~~36. The pharmaceutical composition of claim ~~86~~35, wherein the adjuvant is selected from the group consisting of aluminum hydroxide, aluminum phosphate, aluminum sulfate, 3 De-O-acylated monophosphoryl lipid A (MPL), QS-21, TQL-1055, QS-18, QS-17, QS-7, Complete Freund's Adjuvant (CFA), Incomplete Freund's Adjuvant (IFA), oil in water emulsions (such as squalene or peanut oil), CpG, polyglutamic acid, polylysine, AddaVax™, MF59®, and combinations thereof.

~~88. The pharmaceutical composition of claim 87, wherein the adjuvant is QS-21 or TQL-1055.~~

~~89. The pharmaceutical composition of claim 87, wherein the adjuvant is MPL.~~

~~90~~37. The pharmaceutical composition of claim ~~87~~36, wherein the adjuvant is a combination of MPL and QS-21 or a combination of MPL and TQL-1055.

~~91~~38. The pharmaceutical composition of ~~any of claims 86 to 90,~~claim 35, wherein the adjuvant comprises a liposomal formulation.

~~92~~39. The pharmaceutical composition of any of claims ~~86 to 91~~35-38, wherein the composition comprises at least one pharmaceutically acceptable diluent.

~~93~~40. The pharmaceutical formulation of any of claims ~~86 to 92~~35-39, comprising a multiple antigen presenting system (MAP).

~~94~~41. The pharmaceutical formulation of claim ~~93~~40, wherein the MAP comprises one or more of a Lys-based dendritic scaffold, helper T-cell epitopes, immune stimulating lipophilic moieties, cell penetrating peptides, radical induced polymerization, self-assembling nanoparticles as antigen-presenting platforms and gold nanoparticles.

~~95~~42. A nucleic acid comprising a nucleic acid sequence encoding a peptide of any one of claims 1 to ~~76~~ 28 or the immunotherapy composition of claims ~~77 to 85~~28-34.

~~96~~43. A nucleic acid immunotherapy composition comprising the nucleic acid of claim ~~95~~ 42 and at least one adjuvant.

~~97~~44. ~~A method of treating or effecting prophylaxis of Alzheimer's disease in a subject, comprising administrating to the subject~~Use of the immunotherapy composition of any of claims ~~77 to 85~~28-34 or the pharmaceutical compositions of any of claims ~~86 to 94~~35-41 in the manufacture of a medicament for treating or effecting prophylaxis of Alzheimer's disease in a subject.

~~98~~45. ~~A method of inhibiting or reducing aggregation of tau in a subject having or at risk of developing Alzheimer's disease, comprising, administering to the subject~~ Use of the immunotherapy composition of any of claims ~~77 to 85~~28-34 or the pharmaceutical formulations of any of claims ~~86 to 94~~35-41in the manufacture of a medicament for inhibiting or reducing aggregation of tau in a subject having or at risk of developing Alzheimer's disease.

~~99~~46. ~~A method of treating or effecting prophylaxis of Alzheimer's disease in a subject, comprising administrating to the subject~~Use of the nucleic acid immunotherapy composition of ~~claim 95 or 96~~claim 43 in the manufacture of a medicament for treating or effecting prophylaxis of Alzheimer's disease in a subject.

~~100~~47. ~~A method of inhibiting or reducing aggregation of tau in a subject having or at risk of developing Alzheimer's disease, comprising administering to the subject~~Use of the nucleic acid immunotherapy composition of claim ~~96 or 96~~43 in the manufacture of a medicament for

inhibiting or reducing aggregation of tau in a subject having or at risk of developing Alzheimer's disease.

~~101. The method of any of claims 97 to 100, further comprising repeating the administering at least a second time, at least a third time, at least a fourth time, at least a fifth time, or at least a sixth time.~~

~~102. The method of claim 101, further comprising repeating the administering at an interval of about 21 to about 28 days.~~

~~103~~48. ~~A method of inducing an immune response in an animal, comprising administering to the animal~~ Use of any one of the peptide of claims ~~1 to 76~~1-27, the immunotherapy composition of any of claims ~~77 to 85~~28-34, the pharmaceutical formulations of any of claims ~~86 to 94~~35-41 or the nucleic acid immunotherapy composition of claim~~s 95 to 96~~ 43 in the manufacture of a medicament for inducing an immune response in an animal, wherein the medicament is to be administered in a regimen effective to generate an immune response comprising antibodies that specifically bind to tau.

~~104. The method of claim 103, wherein the immune response comprises antibodies that specifically bind to tau.~~

~~105~~49. The ~~method of any of claims 103 to 104~~use of claim 48, wherein ~~the inducing~~ the immune response comprises antibodies that specifically bind to the microtubule region of tau.

~~106~~50. An immunization kit comprising the immunotherapy composition of any of claims ~~77 to 85~~28-34.

~~107~~51. The kit of claim ~~106~~50, further comprising an adjuvant.

~~108~~52. The kit of claim ~~107~~51, wherein the immunotherapy composition is in a first container and the adjuvant is in a second container.

~~109~~53. A kit comprising the nucleic acid immunotherapy composition of claim ~~96~~43.

~~110~~54. The kit of ~~claim109~~claim 53, further comprising an adjuvant.

~~111~~55. The kit of claim ~~110~~54, wherein the nucleic acid is in a first container and the adjuvant is in a second container.

56. The peptide of any one of claims 1-27, the immunotherapy composition of any one of claims 28-34, the pharmaceutical formulations of any of claims 35-41, or the nucleic acid immunotherapy composition of claim 43 for use in therapy.